American heart journal最新文献

{"title":"Plasma Protein Biomarkers for Nutritional Status in Long Covid-19: Predictors of Cardiovascular Complications","authors":"Shaaf Ahmad,&nbsp;Kaleem Maqsood","doi":"10.1016/j.ahj.2024.09.025","DOIUrl":"10.1016/j.ahj.2024.09.025","url":null,"abstract":"<div><div>This study aimed to identify plasma protein biomarkers for nutritional status as potential prognosticators of mortality in long-COVID-19, addressing the gap in understanding the disease's long-term cardiovascular risks and the role of immunity and nutrition in its progression.</div><div>In this study, initially, 329 individuals were recruited, meeting the inclusion criteria, comprising 89 healthy controls, 186 patients with mild infection, and 54 with severe disease. Two months post-COVID, follow-up was conducted, categorizing patients into survivors (n=212) and non-survivors (n=28). 2-Dimensional Gel Electrophoresis (2DE) of plasma samples for protein separation was performed; after that, proteins were identified through LC-MS/MS. Mascot version 2.3.02 was followed by analysis using Samespots software 4.5.1 to calculate protein volume and area coverage. GraphPad Prism 5.0 was used for statistical analysis.</div><div>LC-MS/MS confirmed Transthyretin (TTR) and serotransferrin (TF) as potential predictive biomarkers as the study found significant downregulation of TF and TTR in COVID-19 patients in comparison to healthy subjects, with a further decrease observed in severe cases compared to mild cases. Non-survivors also showed a significantly lower level.</div><div>The study uncovered serum nutritional biomarkers capable of accurately predicting COVID-19 prognosis and long-COVID mortality due to cardiovascular complications, facilitating tailored nutritional care and guidance for individuals combating SARS-CoV-2. These findings underscore the significance of developing tailored nutritional protocols to enhance dietary practices, complemented by using probiotics and prebiotics, to manage COVID-19 and other infections.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 9"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bariatric Surgery-Induced Weight Loss Reduces CD36 Expression in Association with the Improvement of Insulin Resistance in Monocytes of Obese Subjects","authors":"Tahar Hajri,&nbsp;Ewing Douglas,&nbsp;Toghrul Talishinski,&nbsp;Eid Sebastian,&nbsp;Schmidt Hans","doi":"10.1016/j.ahj.2024.09.021","DOIUrl":"10.1016/j.ahj.2024.09.021","url":null,"abstract":"<div><div>Obesity is often associated with oxidative stress and lipid peroxidation, which are known risk factors for insulin resistance and type 2 diabetes. Cell differentiating-36 (CD36) is a cell membrane receptor that is also implicated in early stages of insulin resistance and diabetes due to its ability to bind and internalize oxidatively modified low-density lipoprotein (oxLDL). Bariatric surgery is an effective procedure that induces substantial weight loss and improves obesity-associated comorbidities. This study investigated the effect of Roux-en-Y Gastric Bypass Surgery (RYGB) on plasma oxLDL and CD36 expression and assessed possible link with insulin activity.</div><div>Th study was conducted prospectively in thirty-six obese subjects who underwent RYGB. Weight loss was recorded before and at 6 and 12 months postoperatively. The expression of CD36 in monocytes was analyzed by flow cytometry and polymerase chain reaction (PCR). The concentrations of blood lipids, glucose, insulin and oxLDL were assayed in plasma, and the homeostatic model assessment insulin resistance index (HOMA-IR) was determined.</div><div>There was a significant reduction of monocyte CD36 levels at 6 months (-48%) and 12 months (-63%) post-surgery. The concentrations of plasma insulin, oxLDL and triglycerides were reduced after 6 months (-38%, -41% and -29%, respectively) and after 12 months (-51%, -61% and -36%, respectively) post-surgery. The level of monocyte CD36 was positively correlated with body mass index (BMI), blood insulin and HOMA-IR.</div><div>The reduction of monocyte CD36 expression and plasma oxLDL level following RYGB-induced weight loss may contribute to the improvement of insulin resistance cardiovascular disease risk factors.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Pages 7-8"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria","authors":"Ashwin K. Chetty,&nbsp;Mihir Khunte,&nbsp;Yuan Lu,&nbsp;Alissa S. Chen","doi":"10.1016/j.ahj.2024.09.026","DOIUrl":"10.1016/j.ahj.2024.09.026","url":null,"abstract":"<div><div>The STEP-10 trial among adults with obesity and prediabetes found that Wegovy led to greater reversion to normoglycemia and prevention of type 2 diabetes than placebo. The extent to which STEP-10 findings may be generalized to the US population with obesity and prediabetes is unclear. Therefore, we estimated the size and sociodemographic and metabolic characteristics of the US population that would be eligible for Wegovy based on STEP-10 criteria. We used the National Health and Nutrition Examination Survey from January 2017 to March 2020. Our sample included adults (aged ≥18) with a documented BMI and FPG. Those eligible for STEP-10 were defined as not receiving anti-diabetes or anti-obesity medication in the past month and having obesity (BMI ≥30 kg/m2) and prediabetes, defined as 6.0% ≤ HbA1c ≤ 6.4% or 99 mg/dL ≤ FPG ≤ 125 mg/dL. The study sample included 3,892 participants aged ≥18, representing 245,418,973 adults. Among this population, 20.4% (95% CI, 18.0-22.8%) or 49.9 million people were eligible for Wegovy based on STEP-10 criteria. Compared to the US population with obesity and prediabetes, STEP-10 overrepresented females and people of White race and enrolled participants with greater mean body weight, BMI, waist circumference, and HbA1c. These findings indicate that there is a large US population with non-medically treated obesity and prediabetes who could benefit from the type 2 diabetes preventative effects of Wegovy. However, the generalizability of STEP-10 to the US is limited by under-representation of Males and people of Black and Hispanic race/ethnicity.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 10"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Heart Rate Variability between Non-ST-Elevation Myocardial Infarction Patients with and without Type 2 Diabetes Mellitus","authors":"Neha Narayan ,&nbsp;Naga Teja Yedida ,&nbsp;Raghu Ram Shanmukh Nemani ,&nbsp;Tejaswi Vadde ,&nbsp;Rithwik Goud Burri ,&nbsp;Sriharsha Lankala ,&nbsp;Sai Praneeth Duvvuri ,&nbsp;Krishna Chaitanya Meduri ,&nbsp;Yethindra Vityala","doi":"10.1016/j.ahj.2024.09.012","DOIUrl":"10.1016/j.ahj.2024.09.012","url":null,"abstract":"<div><div><strong>Background:</strong> Variations in heart rate variability (HRV), indicative of potential life-threatening conditions, are associated with an increased risk of ventricular arrhythmias and sudden death. Patients with myocardial infarction (MI) and type 2 diabetes mellitus (T2DM) may also exhibit significant changes in HRV markers that are commonly associated with unfavorable outcomes.</div><div><strong>Objective:</strong> We evaluated the differences in HRV features between Non-ST-elevation MI (NSTEMI) patients with and without T2DM.</div><div><strong>Methods:</strong> This study included 88 individuals diagnosed with NSTEMI, with an average age of 58 years. The participants were divided into two groups: Group I, 39 patients with T2DM (59% men) and Group II, 49 patients without DM (53% men). The Myocard-Holter-2 device was used for 24-hour Holter monitoring from to 10-14 days of hospitalization. This study evaluated the daily mean HR and transient HRV markers, including SDNN, SDNNi, rMSSD, and pNN50.</div><div>Results: The two groups were similar in terms of sex and age (p=0.312 and p=0.338, respectively). Patients with T2DM had a higher average daily HR of 82±9/min compared to 75±8/min (p=0.002). Patients in group 1 had lower average values for all HRV time parameters, including SDNN (87.2±18.1 ms vs 89.2±10.6 ms, p=0.006), SDNNi (27.5±5.1 ms vs 43.7±6.3 ms, p=0.004), rMSSD (21.4±3.2 ms vs 19.8±2.6 ms, p&lt;0.001), and pNN50 (6.2±2.8% vs 5.3±2.4%, p&lt;0.001).</div><div><strong>Conclusions:</strong> Patients with NSTEMI and T2DM had lower HRV scores, suggesting that they may be at a higher risk for developing non-life-threatening cardiac arrhythmias and experiencing cardiac autonomic neuropathy.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Pages 2-3"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obicetrapib Alone and in Combination with Ezetimibe Reduces Atherosclerotic Lesion Prevalence, Size and Severity in ApoE*3-Leiden.CETP Mice","authors":"José A. Inia,&nbsp;Nanda Keijzer,&nbsp;Nicole Worms,&nbsp;Anita van Nieuwkoop,&nbsp;Marc Ditmarsch,&nbsp;J. Wouter Jukema,&nbsp;John Kastelein,&nbsp;Elsbet J. Pieterman,&nbsp;Hans M.G. Princen","doi":"10.1016/j.ahj.2024.09.016","DOIUrl":"10.1016/j.ahj.2024.09.016","url":null,"abstract":"<div><div><strong>Background and Aims:</strong> Obicetrapib is a selective, potent, cholesteryl ester transfer protein (CETP) inhibitor in clinical development for the treatment of hypercholesterolemia and reduction of cardiovascular risk. It strongly reduces apolipoprotein B (ApoB) and low-density lipoprotein cholesterol (LDL-C) and increases plasma high-density lipoprotein cholesterol (HDL-C). Ezetimibe is a potent, selective inhibitor of biliary and dietary cholesterol absorption from the small intestine, also reducing LDL-C levels. The current study evaluated the effect of obicetrapib monotherapy and in combination with ezetimibe on atherosclerosis development in a mouse model for hyperlipidemia and atherosclerosis.</div><div><strong>Methods:</strong> Female ApoE*3-Leiden.CETP transgenic mice were fed a Western diet with 0.05% w/w cholesterol (equivalent to daily human intake) or this diet containing obicetrapib alone (2 mg/kg/day), ezetimibe alone (on average 0.6 mg/kg/day), or the combination of obicetrapib and ezetimibe. After 28 weeks of treatment, atherosclerosis development was measured in the aortic roots.</div><div><strong>Results:</strong> Obicetrapib, ezetimibe, and the combination reduced total plasma cholesterol levels (-31%, -19% and -53%), mainly attributed to a decrease in non-HDL-C levels (-53%, -19% and -75%). Obicetrapib and combination treatment nearly completely blocked CETP activity (-98% and -98%). Obicetrapib, ezetimibe, and the combination reduced atherosclerotic lesion size (-90%, -50% and -98%) and reduced severe lesions (-82%, -31% and -98%). The percentage of unaffected segments was increased by obicetrapib and the combination treatment (+347%, +442%).</div><div><strong>Conclusions:</strong> Obicetrapib alone and the combination with ezetimibe robustly lowers non-HDL-C levels and impedes atherosclerosis development through a large decrease in atherosclerotic lesion size and severity.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 5"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes in Non-Obese Caucasian and Hispanic Populations with DM, a Nation-Wide Study","authors":"Sindhu Kishore MD.,&nbsp;Leonid Khokhlov MD.,&nbsp;Mehwish Kishore MD.,&nbsp;Sila Mateo Faxas MD.,&nbsp;Kamal Shemisa MD.","doi":"10.1016/j.ahj.2024.09.010","DOIUrl":"10.1016/j.ahj.2024.09.010","url":null,"abstract":"<div><div>The global prevalence of DM is approximately 10.5% and is expected to rise in the next few years. There is limited data on its outcomes stratified by race. Controlling DM will mitigate the risks of atherosclerotic cardiovascular disease. The purpose of this study is to compare differences in clinical outcomes in non-obese Caucasian and Hispanic populations with DM. Conducted as an observational study, it utilized data from the National Inpatient Sample from 2017 to 2020 focusing on non-obese adults over 18 years, with a BMI &lt;30 kg/m^2, and DM diagnosis, excluding those under 18, obese or without DM. Primary outcome was in-hospital mortality. Secondary outcomes were cardiogenic shock, cardiac arrest, GIB, mechanical ventilation, length of stay, and total cost. Multivariable logistic and Poisson regression analyses determined the clinical outcomes, considering a p-value &lt;0.05 significant. Among 22,300,000 non-obese adults with DM, 64.2% were Caucasians, 13.3% were Hispanics, 3.5% were Asians, 18.8% were AA, and the remaining population belonged to other ethnicities. This study revealed higher rates in the Caucasians for conditions like metabolic syndrome, dyslipidemia, HTN, pHTN, HF, PVD, A.fib, ACS, AKI, stroke, PE, and COPD. The Hispanics were seen to have a higher incidence of anemia, CKD, and severe sepsis. In terms of primary and secondary outcomes, Hispanics were higher. The findings undermine the importance of racial differences in such conditions and more in-depth studies are needed to extrapolate the gaps in care.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Pages 1-2"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Differences in the Impact of Type 2 Diabetes on Long-Term Mortality in Patients with Heart Failure and Preserved Ejection Fraction","authors":"Yethindra Vityala ,&nbsp;Altynai Zhumabekova ,&nbsp;Chethan raj Gundoji ,&nbsp;Sushmitha Bhavanthi ,&nbsp;Sai Praneeth Duvvuri ,&nbsp;Krishna Chaitanya Meduri ,&nbsp;Rithwik Goud Burri ,&nbsp;Nagasree Golla ,&nbsp;Tugolbai Tagaev","doi":"10.1016/j.ahj.2024.09.011","DOIUrl":"10.1016/j.ahj.2024.09.011","url":null,"abstract":"<div><div><strong>Background:</strong> Type 2 diabetes (T2D) is frequently present as a comorbid condition in patients diagnosed with heart failure with preserved ejection fraction (HFpEF). Recent investigations have demonstrated that females with diabetes are more susceptible to the development of HF compared to males. Nevertheless, there is a lack of extensive research on the prospects of T2D patients with HF, specifically in relation to gender.</div><div><strong>Objective:</strong> We examined the varying effect of T2DM on overall mortality in males compared to females with HFpEF following hospitalization for acute HF.</div><div><strong>Methods:</strong> This prospective study included 266 patients with HFpEF who were admitted to and discharged from our hospital after being diagnosed with acute HF. This study employed a Multivariate Cox regression model to assess the association between gender, T2D, and the risk of long-term overall morbidity. Hazard ratios (HR) were used to express risk estimation.</div><div><strong>Results:</strong> The average age of the group was 68.3±7.2 years and 151 (56.8%) were female. The prevalence of T2D was comparable between males and females (47.2% vs. 53.7%; p=0.168). Following a median follow-up period of 4.2 years (with an interquartile range of 2.0-7.4 years), 158 (59.4%) patients reported mortality. In females, T2D was associated with a significantly increased risk of death from any cause (HR=2.62; 95% confidence interval, 2.36-3.16; P&lt;0.002). However, in males, there was no significant association between T2D and mortality (HR=2.08; 95% confidence interval, 1.69-2.49; P=0.087).</div><div><strong>Conclusions:</strong> Following the diagnosis of acute HF in patients with HFpEF, females with T2D had an increased risk of mortality.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 2"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Racial and Regional Disparities in Sudden Cardiac Death Related Mortality, Trends in Patients with Type 2 Diabetes Mellitus: 1999-2020.","authors":"Shaaf Ahmad","doi":"10.1016/j.ahj.2024.09.023","DOIUrl":"10.1016/j.ahj.2024.09.023","url":null,"abstract":"<div><div>Subnormal glycemic control, as is seen in Type 2 Diabetes Mellitus (T2DM), has been established as a risk factor of sudden cardiac death (SCD) due to the microvascular complications of T2DM affecting the heart's conduction system, instigating arrhythmias. With increasing incidence of SCD in diabetics in the U.S., the racial and rural-urban disparities remain less well-established. This paper examines the difference in mortality trends when stratified by these two demographics.</div><div>CDC WONDER database was queried from 1999-2020 to obtain SCD related mortality trends data in diabetics. Age-adjusted mortality rates (AAMR) per 100,000 were obtained using the U.S. population in 2000 as the standard. Joinpoint regression was employed to ascertain differences in interracial trends &amp; rural vs urban cities.</div><div>12,545 diabetics suffered from sudden cardiac death in the past 2 decades, with West Virginia (AAMR: 0.37) and Tennessee (AAMR: 0.38) recording the highest rates. Overall AAMR upturned from 1999 (AAMR: 0.14) to 2020 (AAMR: 0.22). Mortality rates were higher in the African Americans (AAMR: 0.21 [0.19,0.22]; AAPC: 2.2 [0.56,4.27]) than Whites: (AAMR: 0.17 [0.16,0.17]; AAPC: 2.3 [1.3,3.78]), AAPC declined for Hispanics (AAPC: -0.62 [-4.7,3.6]). Midwest (AAMR: 0.22 [0.21,0.23]) had the highest rates, followed by South (AAMR: 0.16 [0.16,0.17]), Northeast (AAMR: 0.14 [0.1,0.18]) and West (AAMR: 0.09 [0.09,0.1]). AAMR in rural counties (AAMR: 0.32 [0.31,0.34]; AAPC: 3.6 [2.6,5.2]) was 3.5 times higher than in large metropolitans (AAMR: 0.09 [0.09,0.1]; AAPC: 1.9 [0.8,3.5]).</div><div>Racial disparity alongside three-fold higher AAMRs in rural counties require robust mechanisms of healthcare delivery to impoverished regions and entities.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Pages 8-9"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies","authors":"E. Niesor,&nbsp;M. Ditmarsch,&nbsp;S. Rezzi,&nbsp;S. Canarelli,&nbsp;A. Hodgson,&nbsp;P. Hänggi,&nbsp;J. Kastelei 4","doi":"10.1016/j.ahj.2024.09.014","DOIUrl":"10.1016/j.ahj.2024.09.014","url":null,"abstract":"<div><div><strong>Background and Aims:</strong> Non-lipidated ApoA1 (pre-beta1 HDL) captures cholesterol and lipophilic antioxidants via ABCA1. HDL particles transport antioxidants to tissues such as retina and brain. The effect of HDL raising interventions on pre-beta1 HDL levels and the distribution of lipophilic antioxidants amongst lipoproteins is unknown. CETP-inhibition was hypothesized to reduce the antioxidant capacity of HDL, although direct evidence was never presented. This is now addressed in phase II studies of the novel CETP-inhibitor obicetrapib</div><div><strong>Methods:</strong> Plasma samples from two phase II studies with obicetrapib were used to measure changes in pre-beta1 HDL by ELISA with a selective antibody to ApoA1 aa 137-144 (LQEKLSPL).. Lipophilic antioxidants were quantified in plasma, non-HDL, and HDL-fractions by ULPC ms-ms.</div><div><strong>Results:</strong> In both studies, no significant changes occurred in placebo groups but, in the obicetrapib treated groups, plasma pre-beta1 HDL increased by 12% (p&lt;0.04) and 24% (p&lt;0.03). In OCEAN, plasma ApoA1 and HDL-C levels correlated with increasing levels of antioxidants in the HDL fraction.</div><div>In ROSE2, α-tocopherol was raised in plasma by 16% (p&lt;0.003) and in HDL by 58% (p&lt;0.00003). In both studies pre-beta1 HDL in obicetrapib treated patients was correlated with α-tocopherol in plasma.</div><div><strong>Conclusions:</strong> CETP inhibition with obicetrapib increases pre-beta1 HDL, impacts excess cholesterol efflux, and also raises important HDL antioxidants. Thus, these results support the potential therapeutic use of obicetrapib in diseases with high unmet medical need that are associated with low HDL and low levels of lipophilic antioxidants in plasma and tissues, such as AMD, neurodegenerative disorders, and sickle cell anemia.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 4"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post Covid-19 Upturn in Acute MI Related Mortality Trends in Young to Middle Aged Type-2 Diabetics: Observations from CDC Wonder","authors":"Shaaf Ahmad","doi":"10.1016/j.ahj.2024.09.024","DOIUrl":"10.1016/j.ahj.2024.09.024","url":null,"abstract":"<div><div>COVID-19 outbreak negatively impacted all aspects of adequate delivery of healthcare by overburdening the modalities. Care for acute myocardial infarction was heavily impacted attributable, in part, to reduced hospitalizations and cardiac care units not being able to function at full capacity. This paper attempts to elicit the resultant trend shift in Acute myocardial infarction (AMI) related mortality in young to middle-aged diabetics.</div><div>CDC WONDER database was queried from 1999-2021. Only patients younger than 54 years old were included. Age-adjusted mortality rates (AAMR) per 100,000 with 95% confidence intervals were obtained. Joinpoint 5.0 software was used to analyze trend shift with average annual percent change (AAPC) values.</div><div>A total of 10,011 AMI related deaths were encountered in the young/middle aged diabetics during our study period. Of which, around 14% (1,381) deaths were recorded in the years 2020 &amp; 2021 alone. In these 2 years, 20.24% of subjects passed away in their homes vs only 11.06% deaths recorded in-patient. Overall AAMR more than doubled from 1999 (AAMR: 0.14 [0.13,0.16]) to 2021 (AAMR: 0.32 [0.3,0.34]) (AAPC: 3.7 [2.9,5.5]). Males had higher mortality rates (AAMR1999-2020: 2.55 [2.52,2.57]) than females (AAMR1999-2020: 1.49 [1.47-1.50]). Rural counties (AAMR1999-2020: 3.68 [3.63,3.74]) had nearly triple the mortality rates of large metropolitans (AAMR1999-2020: 1.70 [1.68,1.72]). AAMR were highest in the Midwest (AAMR1999-2020:2.3 [2.27,2.32]) and lowest in the Northeast (AAMR1999-2020: 1.41 [1.39,1.43]).</div><div>COVID-19 had profound effects on cardiovascular healthcare. Post-pandemic, developing robust mechanisms to reverse the damage dealt in terms of increased morbidity and mortality has become imperative.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 9"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}